secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2026-06-15T20:02:48+00:00
Accession:  0001193125-26-271055
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics shareholders approve 7M share increase to stock plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved 3rd A&R 2022 Stock Plan adding 7M shares; votes: 46.6M for, 14.3M against (26.1M broker non-votes).
- Directors Epstein, Jooss, Hamill re-elected with 59.3M, 59.7M, 60.9M votes for, respectively.
- Ernst & Young ratified as independent auditor for FY2026; 86.6M for, 0.3M against.
- Non-binding advisory vote on executive compensation passed with 59.2M for, 1.8M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/0001193125-26-271055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312526271055/fate-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-271055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer